S.H. Goey - Concepedia

Author

S.H. Goey

Elisabeth-TweeSteden Ziekenhuis

Also Known As

S H Goey, S. Goey, S. H. Goey, S. Hoo Goey, S.H. Goey, Swan H Goey, Swan H. Goey, Swan Hoo Goey

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Elisabeth-TweeSteden Ziekenhuis Rotterdam University of Applied Sciences Radboud University Nijmegen Erasmus MC Cancer Institute The Netherlands Cancer Institute

About

S.H. Goey is an author at Elisabeth-TweeSteden Ziekenhuis specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	517
2	Health Sciences	2	2	75
3	Public Health	2	2	159
4	Epidemiology	1	1	134
5	Health Policy	1	1	25

S.H. Goey

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Ulrich Keilholz, S.H. Goey, Cornelis J.A. Punt, Journal of Clinical Oncology	1997	196
Regression of Advanced Ovarian Carcinoma by Intraperitoneal Treatment With Autologous TLymphocytes Retargeted by a Bispecific Monoclonal Antibody Silvana Canevari, Gerrit Stoter, Flavio Arienti, JNCI Journal of the National Cancer Institute	1995	191
The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study Huub Maas, Roy F.P.M. Kruitwagen, V.E.P.P. Lemmens, Gynecologic Oncology Population-based StudyCancer EpidemiologyMedicineCancer ManagementEpidemiology Of Cancer	2005	134
Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. R. L. H. Bolhuis, C. B. H. W. Lamers, S.H. Goey, PubMed Immunocytochemical TechniqueBs-mab-targeted LymphocytesImmunologyImmunoeditingGynecology	1992	109
Phase II to III Study Comparing Doxorubicin and Docetaxel With Fluorouracil, Doxorubicin, and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre M. Bontenbal, Geert‐Jan Creemers, Hans J. Braun, Journal of Clinical Oncology	2005	102
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer Robert J. van Soest, Annemieke J.M. Nieuweboer, Ellen S. de Morrée, European Journal of Cancer UrologyOncologyMedicinePharmacotherapyAnti-cancer Agent	2015	63
Interleukin-2 and Interferon-α in the Treatment of Patients with Advanced Non-Small-Cell Lung Cancer Rob L. H. Jansen, Rob Slingerland, S.H. Goey, Journal of Immunotherapy	1992	56
Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication Wim H.J. Kruit, K. Punt, S.H. Goey, Cancer	1994	55
Duodenal metastasis: an uncommon cause of occult small intestinal bleeding. A. Loualidi, P. F. M. J. Spooren, M.J.A.L. Grubben, PubMed	2004	51
Weekly high-dose cisplatin in malignant pleural mesothelioma André Planting, Jan H.M. Schellens, S.H. Goey, Annals of Oncology Weekly High-dose CisplatinPleural DiseaseCancer TreatmentOncologyRadiation Oncology	1994	46

Page 1